收费全文 | 51691篇 |
免费 | 3606篇 |
国内免费 | 109篇 |
耳鼻咽喉 | 392篇 |
儿科学 | 1941篇 |
妇产科学 | 1797篇 |
基础医学 | 6139篇 |
口腔科学 | 633篇 |
临床医学 | 9008篇 |
内科学 | 9505篇 |
皮肤病学 | 783篇 |
神经病学 | 4593篇 |
特种医学 | 957篇 |
外国民族医学 | 34篇 |
外科学 | 4590篇 |
综合类 | 656篇 |
一般理论 | 79篇 |
预防医学 | 7205篇 |
眼科学 | 584篇 |
药学 | 2906篇 |
1篇 | |
中国医学 | 89篇 |
肿瘤学 | 3514篇 |
2023年 | 307篇 |
2022年 | 441篇 |
2021年 | 1002篇 |
2020年 | 677篇 |
2019年 | 1092篇 |
2018年 | 1252篇 |
2017年 | 868篇 |
2016年 | 983篇 |
2015年 | 1057篇 |
2014年 | 1468篇 |
2013年 | 2462篇 |
2012年 | 3510篇 |
2011年 | 3736篇 |
2010年 | 1991篇 |
2009年 | 1866篇 |
2008年 | 3286篇 |
2007年 | 3759篇 |
2006年 | 3613篇 |
2005年 | 3520篇 |
2004年 | 3385篇 |
2003年 | 3222篇 |
2002年 | 3031篇 |
2001年 | 462篇 |
2000年 | 329篇 |
1999年 | 437篇 |
1998年 | 669篇 |
1997年 | 527篇 |
1996年 | 471篇 |
1995年 | 379篇 |
1994年 | 380篇 |
1993年 | 378篇 |
1992年 | 296篇 |
1991年 | 262篇 |
1990年 | 250篇 |
1989年 | 209篇 |
1988年 | 199篇 |
1987年 | 215篇 |
1986年 | 180篇 |
1985年 | 205篇 |
1984年 | 226篇 |
1983年 | 228篇 |
1982年 | 271篇 |
1981年 | 254篇 |
1980年 | 204篇 |
1979年 | 152篇 |
1978年 | 125篇 |
1977年 | 141篇 |
1976年 | 123篇 |
1975年 | 110篇 |
1973年 | 107篇 |
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献Method: Thirty-two pediatric patients with stroke (Mage = 9.5 ± 2.7 years) and 32 demographically equivalent, healthy controls were tested on standardized measures of arithmetic, spelling, and intelligence. Executive functioning data were collected via standardized parent questionnaire.
Results: Relative to controls, stroke participants demonstrated significantly poorer functioning in math, spelling, metacognition, and behavioral-regulation. Pencil and paper arithmetic was particularly challenging for the stroke group, with 40% of patients reaching levels of clinical impairment. Hierarchical regression in stroke participants further revealed that metacognition was a robust predictor of academic deficits. Stroke occurring in later childhood and affecting cortical and subcortical brain regions also presented as potential clinical risk factors.
Conclusions: Children with stroke were especially vulnerable to math achievement deficits. Metacognition made a substantial contribution to academic achievement abilities among stroke patients, and results underscore the importance of early metacognitive skills in the completion of schoolwork. Results also emphasize that pediatric stroke patients are a heterogeneous group with regard to functioning and that there is value in examining standard score distributions of clinical participant samples. 相似文献